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ABSTRACT

A method of making a hyperbranched amphiphilic polyester
compound includes drying under vacuum a mixture of 2-( 4hydroxybutyl)-malonic acid and p-toluene sulphonic acid as
catalyst. The vacuum is then released with a dry inert gas after
drying. The dried mixture is heated under the inert gas at a
temperature sufficient for polymerization. The inert gas is
evacuated while continuing to heat the mixture. The formed
polymer is then dissolved in dimethylformamide and precipitated out by adding methanol. Modifications of the method
yield nanoparticles of polyesters having properties suited for
coencapsulating fluorescent dyes together with therapeutic
drugs, resulting in theranostic nanoparticles, that is, nanoparticles useful in both therapeutic treatments and diagnostic
methods.
17 Claims, 29 Drawing Sheets
(16 of 29 Drawing Sheet(s) Filed in Color)
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SYNTHESIS OF HYPERBRANCHED
AMPHIPHILIC POLYESTER AND
THERANOSTIC NANOPARTICLES THEREOF

ment, where novel targeted multifunctional polymeric nanoparticles can be developed to obtained spatiotemporal information about disease stage and progress of a therapeutic
regime.12-14 Hence, there has been substantial interest in
developing smart therapeutic and selective polymeric
vehicles fortargeted treatment of various diseases, preventing
toxicity to healthy tissues.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This is a division of application Ser. No. 12/417,017 filed
Apr. 2, 2009, entitled "Synthesis of Hyperbranched
Amphiphilic Polyester and Theranostic Particles Thereof,"
which claims the benefit of provisional application Ser. No.
61/041,624 filed on Apr. 2, 2008. Both of these applications
are incorporated herein by reference in their entireties.
STATEMENT OF GOVERNMENT RIGHTS

SUMMARY OF THE INVENTION
10

15

This invention was made with government support under
CAI 01781 awarded by the National Institutes of Health. The
government has certain rights in the invention.
20

FIELD OF THE INVENTION
The present invention relates to the field of nanotechnology
and, more particularly, to nanoparticles useful as carriers of
fluorescent dyes for diagnostic purposes and therapeutic
drugs for treatment of disease; these dual-purpose particles
are also known as "theranostic nanoparticles."

25

BACKGROUND OF THE INVENTION
30

Polymer science has traditionally focused on linear polymers or cross-linked linear polymers, resulting in a wide
variety of materials implemented in most facets of daily life.
Recent progress in polymer sciences has resulted in the development of dendrimersl and most recently hyperbranched
polymers2-4 consisting of branched structures with high
numbers of reactive groups in their periphery. The syntheses
of these multifunctional dendritic (branched) polymers hold
great promise for targeted delivery of drugs, therapeutics,
diagnostics and imaging. The perfectly branched structures
called dendrimers are constructed by an iterative and complex
reaction sequence involving protection-deprotection steps
whereas hyperbranched polymers, the less perfect structures,
are made by one step polymerization reaction. Recent
advances in nonviral drug delivery and cancer chemotherapy
have revealed biocompatible branched polymers like polyethyleneimine (PEI) and starburst PAMAM as effective drug
delivery systems, which can mimic naturally occurring biological transport systems such as lipoproteins and viruses.5
Unlike linear polymers which are produced from divalent AB
type monomers, dendritic macromolecules are produced
from polyvalent ABn monomers (n;;,:2), giving rise to its
branching and multiple-end structures.6-8 Dendritic polymers have gained large interest in recent years because of
their highly branched structures facilitating effective encapsulation of guest molecules and having many attractive features such as improved solubility, reactivity, structure architecture, biocompatibility, low viscosity and low crystallinity
compared to those of linear polymers of same molecular
weight.9 Therefore, the creation of new and highly branched
polymeric nano structures with multifunctional capabilities is
central to the development of novel materials with applications in various fields ranging from drug delivery, immunoassays, microelectrons, coating and nanocomposites.10,11
Polymeric nanoparticles and nanocomposites with dual fluorescent, magnetic and therapeutic properties will have a huge
impact in medicine, particularly in cancer diagnosis and treat-
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With the foregoing in mind, the present invention advantageously provides methods for maing hyperbranched
amphiphilic polyester compounds. These polyesters may be
used to generate nanoparticles having one or more hydrophobic pockets and a hydrophilic outer surface. The polymeric
nanoparticles (PNPs) may be used as carriers for a hydrophobic near-infrared fluorescent dye and/or a therapeutic drug.
The PNPs are biodegradable and, having been modified with
appropriate chemical groups along their outer surface, are
readily taken into cells, thus providing an ideal vehicle for
delivery of therapeutic drugs. Since the PNPs may carry both
a fluorescent dye and a therapeutic drug, they can be tracked
optically via the dye and simultaneously deliver the drug to
predetermined cells. The capability of having both a therapeutic modality and a diagnostic modality may be identified
as "theranostic."
A method of the present invention includes making a
hyperbranched amphiphilic polyester compound. The
method includes drying under vacuum a mixture of 2-( 4hydroxybutyl)-malonic acid and p-toluene sulphonic acid as
catalyst. Then, releasing the vacuum with a dry inert gas after
drying. The method continues by heating the dried mixture
under the inert gas at a temperature sufficient for polymerization. The method proceeds by evacuating the inert gas while
continuing to heat the mixture, then dissolving the formed
polymer in dimethylformamide. Finally, the method ends
after precipitating the dissolved polymer by adding methanol.
In the method, drying may comprise a mixture of 2-( 4hydroxybutyl)-malonic acid and p-toluene sulphonic acid in
approximately a 100:1 molar ratio. Also, drying under
vacuum preferably comprises a high vacuum and the inert gas
is argon gas. The heating is preferably at a temperature of
approximately 150° C., which promotes polymerization. The
heating may continue for approximately two hours. Evacuating is most preferably conducted slowly at approximately 0.2
mm/Hg for about one hour while maintaining the polymerization temperature. After polymerization, the method may
further comprise purifying the polymer by separating the
precipitate, washing it with methanol and drying it in a
vacuum.
The described method may be modified to make aminated
PNPs. This is accomplished by dissolving the precipitated
polymer in anhydrous dimethylformamide (DMF), adding
1,1'-carbonyldiimidazole drop-wise to form a reaction mixture and incubating the reaction mixture at room temperature
for approximately one to two hours. This method continues
by adding ethylenediamine in anhydrous DMF drop-wise and
continue incubation of the reaction mixture at room temperature for approximately 24 hours, then precitipating the reaction mixture in methanol, separating the precipitate and drying in a vacuum to obtain a purified hyperbranched polyester
amme.
Yet another modification of the described method is useful
for making propargylated PNPs. This modification includes
dissolving the precipitated polymer in anhydrous dimethylformamide (DMF), adding 1,1'-carbonyldiimidazole dropwise to form a reaction mixture, incubating the reaction mix-

US 9,095,611 Bl
3

4

ture at room temperature for approximately one to two hours,
then adding propargyl chloride in anhydrous DMF drop-wise
and continue incubation of the reaction mixture at room temperature for approximately 24 hours. Lastly, the method calls
for precitipating the reaction mixture in methanol, separating
the precipitate and drying in a vacuum to obtain a purified
hyperbranched propargylated polyester amine.
Having described the method and its two modifications, the
polymers generated thereby represent novel molecules useful
at least for making the PNPs of the invention. Accordingly,
the invention includes a polymer comprising the repeating
unit HBPE (5).

Included in the invention is a polymeric nanoparticle comprising the polymer HBPE-PA(7) and a hydrophobic nearinfrared fluorescent dye encapsulated therein. In this polymeric nanoparticle the dye may be selected from the group
consisting of DiI, DiR, and DiD, and there may also be a
therapeutic drug coencapsulated with said fluorescent dye.
The therapeutic drug preferably comprises an anti-cancer
drug, for example, azidothymidine or 25, wherein the anticancer comprises paclitaxel.
Those skilled in the art will recognize that while certain
hydrophobic near-infrared fluorescent dyes have been given
as examples, other dyes having similar properties would also
be useful in the invention. The same can be expected to hold
for therapeutic drugs other than the ones given here as
examples; as long as the drug exhibits sufficient hydrophobicity to nest in the hydrophobic pocket formed by the polymer in the nanoparticle, the drug should be of use in the
invention. These dyes and drugs as known to the skilled by
their properties are, therefore, intended to be included within
the scope of the invention.
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BRIEF DESCRIPTION OF THE DRAWINGS
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The invention additionally includes a polymeric nanoparticle comprising the polymer HBPE(5), the nanoparticle also
having a hydrophobic near-infrared fluorescent dye encapsulated therein. The dye may be selected from the group consisting of DiI, DiR, and DiD. Additionally, this PNP may
include a therapeutic drug coencapsulated with said fluorescent dye, and particularly, an anti-cancer drug such as azidothymidine.
Another polymer included in the invention is one comprising the repeating unit HBPE-EDA (6).
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Moreover, the invention further includes a polymeric nanoparticle comprising the polymer HBPE-EDA( 6) and a hydrophobic near-infrared fluorescent dye encapsulated therein. As
noted above, the dye may be selected from the group consisting of DiI, DiR, and DiD, and the PNP may also include a
therapeutic drug coencapsulated with said fluorescent dye.
The other modification of the presently disclosed method is
useful for making a polymer comprising the repeating unit
HBPE-PA(7), as set forth below.
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The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee.
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 illustrates, according to a method of the invention,
the facile synthesis of amphiphilic hyperbranched polyester
(HBPE, 5) and corresponding polyester-amine (HBPEA, 6)
polymer, which are highly branched, globular, and biodegradable in nature; the polymeric backbone of HBPE was
synthesized by melt polymerization of the monomer 4, which
can be easily made from commercially available diethylmalonate 1 and bromobutyl acetate (2) in two simple steps, hence
the synthesis of 5 is cost-effective; the corresponding aminated polymer can be synthesized via conjugation of ethylenediamine using 1,1'-carbonyldiimidazile (CDI) coupling;
the resulting amphiphilic and dendritic polymers (5 and 6)
contain inner hydrophobic domain (aliphatic chains), surrounded by a hydrophilic outer shell (carboxylic or amine
groups), which after self assembly in water result in a stable
nanoparticle suspension which can encapsulate hydrophobic
dyes and drugs;
FIG. 2 shows a schematic representation of the structure of
dendritic polyester (HBPE 5) and corresponding formation of
polymeric nanoparticles via solvent diffusion method; using
this method, a series of hydrophobic drugs and dyes can be
encapsulated in one pot; these polymeric nanoparticles are
highly dispersed in water and stable in a wide range of buffered solutions under physiological conditions; both click
chemistry, carbodiimide chemistry and other conjugation
chemistries can be used for the functionalization of these
polymeric nanoparticles with small molecule like antibodies,
proteins, oligonucleotides and other targeting agents to generate a nanoparticle-ligand library;
FIG. 3 presents an overall schematic representation of the
preparation of functional polymers and polymeric nanoparticles (PNPs); polymer 5 was synthesized following the melt
polymerization technique; PNPs were synthesized using the
solvent diffusion method and were stable in water and other

US 9,095,611 Bl
5

6

aqueous buffer solutions; carbodiimide chemistry has been
followed for the synthesis of functional polymers (6 and 7)
using 1,1'-carbonyldiimidazole (CDI), as a water insoluble
carbodiimide. Near IR dyes (DiI, DiD and DiR), paclitaxel
and AzT encapsulated PNPs were prepared in water from the
water insoluble functional polymers using the solvent diffusion method. Click chemistry and carbodiimide chemistry
has been used for the synthesis of a library of functional
PNPs; insets show the structures ofNIR dyes, Paclitaxel and
AzT;
FIG. 4 is a representation of the synthesis of azide-functionalized folic acid (13) from chloropropylamine and Culcatalyzed "click" chemistry for the preparation of folatefunctionalized PNPs (lla-e);
FIG. 5 shows 1 HNMR spectrumoftheAB2 monomer(3);
the characteristic triplet for the single acidic proton (f) was
observed at 3.34 ppm;
FIG. 6 depicts a 13 C NMR spectrum oftheAB2 monomer
(3); all peaks are assigned to the corresponding carbons,
which confirms the presence of the expected compound;
FIG. 7 shows 1 H and 13 C NMR spectra of the final AB2
monomer (4) using CDC1 3 as a solvent; absence of the ethyl
ester protons and acetyl group in the NMR spectra confirms
the hydrolysis of compound 3 and the formation of compound
4; all peaks are assigned to the corresponding protons and
carbons, which confirm the presence of the expected product;
FIG. 8 shows 1 H and 13 C NMR spectra of amphiphilic
hyperbranched polymer (5), confirming the preparation of
high molecular weight polymer; the broadening of the sharp
peaks in 1 H NMR spectrum of the monomers also indicates
the formation of polymer having a large number of chemically equivalent protons with same ll value;
FIG. 9 provides GPC traces of polyester 5, polymerized at
150° C. at atmospheric pressure and under high vacuum; a)
before applying vacuum, showing the presence of low
molecular weight polymers and oligomers; b) high molecular
weight polymer was formed after applying vacuum; for a
comparative study between the average molecular weight
(Mw) and the polymerization time at 150° C., the samples
were taken from the reaction mixture periodically and analyzed by GPC; with increasing time there was an increase in
the molecular weight, whereas a dramatic increase in the
polymer's molecular weight was observed when high
vacuum was applied; moreover, when the evacuation was
continued for more than 2 h, the resulting polymers were
found to be insoluble in all the solvents; the average molecular weight of polymer (5) was Mw=42,000, PD=l.6;
FIG. 10 is a TGA thermogram trace of polyester 5 at a
heating rate of 10° C./min in air; the thermogram obtained is
typical of an aliphatic hyperbranched biopolymer; the hyperbranched polymer exhibits a moderate thermal stability; thermal decomposition of the polymer was initiated at -210° C.;
at 225° C., the polymer has only lost about 2.5% ofits weight,
mainly due to evaporation of the volatile compounds (such as
H20, CHC13 and DMF), before the induction of its thermal
degradation; approximately a 10% weight loss occurred at
250° C.;
FIG. 11 shows inA) the chemical structure ofDiD, DiI and
DiR; these dyes are water insoluble in nature and are primarily used to visualize cell membranes; and in B) a photographic image showing an aqueous (PBS) suspension of
HBPE nanoparticles encapsulating the corresponding dyes
(Sa-c ); similarly, one can encapsulate a hydrophobic drug or
a combination of drug and dye; highly dispersed dyes/drugs
encapsulated polymeric nanoparticles are stable in wide
range of solvents under physiological conditions. The fluorescence of the resulting dye-encapsulated polymeric nano-

particles is bright and is not accompanied by any significant
quenching upon encapsulation of photo bleaching upon prolonged imaging;
FIG. 12 shows the hydrodynamic diameters of the nanoparticles as measured by dynamic light scattering (DLS)
instrument; measurement data shows the average hydrodynamic diameter of the particles are ranging between approximately 90±20 nm;
FIG. 13 presents Scanning Electron Microscope (SEM)
images of the polymeric nanoparticles showing an average
diameter ranging from 115±25 nm, in accordance with the
DLS data shown in FIG. 12; remarkably, the black rectangular box in the image indicates that the nanoparticles are
spherical in shape, as expected;
FIG. 14 depicts FT-IR spectra of the final monomer 4
(Acid), HBPE 5 (Polymer) and the dye encapsulating PNPs
Sa, demonstrating presence of dye within the PNPs; the presence of a FT-IR band at 172S cm- 1 for the ester group indicates the formation of the hyperbranched polyester from the
monomer (band at 1710 cm- 1 for aliphatic carboxylic acid
group); the band at 1675 cm- 1 is attributed to a conjugated
alkene group, confirming the encapsulation of the dye inside
a hydrophobic cavity of the PNPs;
FIG. 15 are UV/Vis spectra of the dye (DiI, DiD, DiR)encapsulating PNPs (Sa-c ), showing the presence of the NIR
dyes with absorption maxima at 552, 650 and 755 nm, respectively;
FIG. 16 shows the characteristic fluorescence emission
spectra of dye encapsulating polymeric nanoparticles (Sa-c)
in DI water; the fluorescence intensity maxima of these nanoparticle solutions at 570 nm, 675 nm and 7SO nm indicate the
presence ofNIR dyes DiI, DiD and DiR, respectively, in the
hydrophobic domain of the polymeric nanoparticles; no
changes in fluorescence intensity or quenching of the dyes
was observed upon encapsulation and subsequent storage of
the nanoparticles at 4 ° C. for months, demonstrating the high
fluorescence stability of these dye encapsulated polymeric
nanoparticles; note the multiple imaging capability using 3
different wavelengths;
FIG. 17 are UV/Vis spectra of the DiI dye encapsulating
PNPs (Sa) and the dye alone; a blue shift (by 10 nm) was
observed in the UV/Vis absorption maxima in the case ofDiI
encapsulating PNPs, which confirmed the presence of the dye
within the hydrophobic domain of the PNPs;
FIG. 18 depicts the blue shift (23 nm) in the fluorescence
emission of DiI encapsulating HBPE nanoparticles (Sa) as
compared to free dye; this is due to both van-der Walls (hydrophobic) and electronic interactions of the dye with the polymeric cavity, confirming the presence of dye inside the polymer cavity;
FIG. 19 shows a photo-stability study of the DiI encapsulating PNPs (Sa) and DiI alone in solution in the presence of
UV light, demonstrating the stability of the dye when encapsulated inside the polymeric cavity compared to the free dye;
FIG. 20 shows the electrokinetic potential (zeta potential)
of the synthesized polymeric nanoparticles; the zeta potential
of the non-aminated polymeric nanoparticles is negative (A,
s=-54.5 mV), as expected, due to the presence of surface
carboxylic acid groups; not surprisingly, the zeta potential of
the aminated polymeric nanoparticles is positive (B, s= 10.33
mV), where the low positive value indicates the partial amination of the nanoparticles with the presence ofless number
of free carboxylic groups than amine groups at the surface;
FIG. 21 presents cell internalization studies using Xenogen's IVIS 50; in these experiments either carboxylated
(negative, Sb) or aminated (positive, 9b) nanoparticles were
incubated with cells from the A549 lung cancer cell line; in
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these representative studies, near infrared DiR encapsulated
nanoparticles were used, although similar results were
observed with DiD and DiI; as expected, internalization was
observed only when the positively charged aminated DiR
nanoparticles were used, as judged by the near infrared fluorescence coming from the cell pellets on FIG. 21B; note that
when carboxylated nanoparticles are used (FIG. 21A), the
fluorescence remains in the supernatant; these results demonstrate that cationic nanoparticles are a better candidate for
the cell internalization studies and for cell tracking studies. In
addition, it shows the capability of imaging in the near infrared;
FIG. 22 is a UVNis spectrum of the folate-clicked, DiIencapsulating PNPs 1 la, showing the presence of both the
encapsulated dye (553 nm) and surface clicked with folate
(354 nm); similar results were obtained for the paclitaxel- and
Dil-encapsulating PNPs 1 ld, prepared for targeted cancer
therapy;
FIG. 23 shows an UVNis spectrum of the folate-clicked,
DiR-encapsulating PNPs 11 b, showing the presence of both
the encapsulated DiR (755 nm) and surface clicked with
folate (355 nm);
FIG. 24 shows bar graphs acknowledging the potential
biomedical applications of the synthesized PNPs; we evaluated their cytotoxicity, through the MTT assay; first, we
examined the potential in vitro differential cytotoxicity of
carboxylated, aminated, and folate-decorated DiI-containing
PNPs, using a lung carcinoma (A549) cell line; results indicated that the carboxylated and folate-conjugated PNPs
exhibited nominal cellular cytotoxicity (less than 4% compared to the control), whereas the aminated PNPs induced cell
death to approximately 10% of the cell population (FIG. 24a);
indeed, the folate-decorated DiI and paclitaxel co-encapsulating PNPs (1 ld) induced a significant reduction in cell
viability, as more than 50% of the cell population underwent
cell death (FIG. 24b); furthermore, as most lung carcinomas
exhibit aberrant telomerase activity, leading to cell immortality, we encapsulated the reverse transcriptase inhibitor AzT in
PNPs (lie); we found that folate-decorated DiI and AzT
co-encapsulating PNPs induced significant cell death, as previously reported in literature via inhibition of telomerase
activity (FIG. 2b); overall, these data suggest that the induction of cell death is mainly mediated by either paclitaxel or
AzT, and not by the fluorophores; control cells were treated
with lxPBS; average values of four measurements are
depicted±standard error;
FIG. 25 shows a confocal laser-scanning microscopic
image of A549 lung cancer cells incubated with DiI dyeencapsulated carboxylated polymeric nanoparticles (Sa); dye
encapsulated nanoparticles are incubated with the cells for 6
h; result shows no internalization of the nanoparticles into the
cytoplasm, which demonstrates that the anionic (carboxylic
groups at surface) polymeric nanoparticles are not the appropriate candidate for cell internalizations; instead, only cell
membrane stained with the dye (outer red lines); the nucleus
stained with DAPI (blue color);
FIG. 26 shows a confocal laser-scanning microscopic
image of A549 lung cancer cells incubated with DiI dye
encapsulated aminated polymeric nanoparticles (9a); internalization of the nanoparticles into the cell cytoplasm was
observed, which demonstrates that the cationic (amine groups
at surface) polymeric nanoparticles are the appropriate candidate for cell internalizations; the nucleus stained with DAPI
(blue color);
FIG. 27 depicts a confocal laser-scanning microscopic
image of A549 lung cancer cells incubated with DiI dye
encapsulated folate-immobilized polymeric nanoparticles

(1 la); the particles were incubated with the cells for 6 h.;
internalization ofthenanoparticles into the cell was observed,
demonstrating the presence of folate receptor in the A549
cancer cells and therefore inducing a folate-receptor mediated internalization;
FIG. 28 provides a confocal laser-scanning microscopic
image of A549 lung cancer cells incubated with folate modified nanoparticles (1 ld) encapsulating both a hydrophobic
dye (DiI) and a hydrophobic anti-cancer drug (paclitaxel); the
nanoparticles were incubated with the cells for 6 h. Neither
the fluorescence intensity of the dye, nor the cytotoxic effects
of the anti-cancer drug are affected when encapsulated in the
polymeric nanoparticle; experiments show that paclitaxelinduced mitotic arrest results in apoptotic cell death of lung
carcinoma cells (A549);
FIG. 29 is a confocal laser-scanning microscopic image of
A549 lung cancer cells incubated with folate modified nanoparticles (Ile) encapsulating both a hydrophobic dye (DiI)
and a hydrophobic anti-HIV drug (AzT); the nanoparticles
were incubated with the cells for 6 h; these experiments show
that AzT-induced mitotic arrest results in apoptotic cell death
oflung carcinoma cells (A549);
FIG. 30 provides an assessment of the PNP-cell association
via flow cytometry, where in a) absence of fluorescence emission is observed in control mock-treated cells (lxPBS), in b)
partial association of the dye-loadednon-aminated PNPs (Sa)
is observed, inc) aminated (9a) and d) folate-decorated (lla)
nanoparticles interact more profoundly with the cells, as indicated by higher levels of fluorescence emission; and
FIG. 31 shows drug (paclitaxel) and dye (DiI) release profiles of functional PNPs (1 ld) in PBS (pH=7.4) at 37° C.;
release of paclitaxel (A & B) and DiI (C & D) were observed
in the presence of an esterase enzyme (A & C) and at pH 4.0
(B & D); these results indicate thatthe PNPs are degradable in
the presence of an esterase enzyme and at low pH; a controlled release of drug and dye was observed.
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The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
Herein, we report the synthesis of novel biodegradable
hyperbranched polyesters and their use for the synthesis of
cell-permeable polymeric nanoparticles that encapsulate
hydrophobic dyes and drugs for dual optical imaging and
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therapeutic applications. To this date, no one has made biocompatible polymeric nanoparticles from diethylmalonate
based hyperbranched polyester. The design and synthesis of
diethylmalonate-based AB 2 monomer is novel and tuned in
such a way that the resulting polymer will have three-dimensional molecular architecture with hydrophobic interior and
hydrophilic segments at the surface (amphiphilic). Selective
mono-C-alkylation of diethylmalonate using a mild basic
condition and followed by hydrolysis of the monomer was
performed to develop a new, water-solubleAB 2 monomer for
the synthesis of the hyperbranched polyester. We have
employed a melt polymerization technique using para-toluenesulfonic acid [p-TSA] as a catalyst to synthesize the novel
aliphatic and biodegradable hyperbranched polyester. We
hypothesized that the presence of AB 2 branching point and a
hydrophobic butyl chain in the monomer structure could be
able to generate a highly branched and hydrophobic polymer.
As a proof-of-principle, the resulting polyester was highly
branched, amphiphilic, having carboxylic acid groups at the
surface and obtaining a three dimensional architecture with
hydrophobic cavity. Therefore, compare to the conventional
linear polymers, our branched polyester is amorphous,
amphiphilic, soluble, biodegradable, highly surface functional and has cavities for effective encapsulation of guest
molecules, which suggest its versatility in biomedical applications. Post-functionalization of this water insoluble polyester has been done using carbodiimide chemistry resulting in
cationic and clickable hyperbranched polyester.
A solvent diffusion method has been adopted for the synthesis of polymeric nanoparticles (PNPs) where the hydrophobic areas assemble together to minimize contact with the
aqueous environment, while exposing the hydrophilic segments containing carboxylic groups at the surface in aqueous
solution. 15 •16 This results in the formation of carboxyl functionalized spherical polymeric nanoparticles in water containing inner hydrophobic domains that can encapsulate
hydrophobic molecules such as dyes and drugs. 17 Note that,
this is the first example of development of hyperbranched
polyester based polymeric nanoparticles using solvent diffusion method. Experimental data showed the effective encapsulation of various hydrophobic near infrared (NIR) dyes and
a therapeutic drug without significant precipitation or reduction of the fluorescent properties. The fluorescence of the
resulting PNPs is bright and stable, allowing the imaging of
cells without significant photo-bleaching. Click chemistry
has been used for the synthesis of folate decorated PNPs for
the targeted cancer therapy. 18- 2 °Finally, we have been able to
encapsulate either a hydrophobic antitumor drug (Paclitaxel)
or, a nucleoside analog reverse transcriptase inhibitor (AzT)
for the treatment of HIV and AIDS, along with near infra red
fluorescent dyes (DiI or DiR) into the folate decorated PNPs
for targeted drug delivery and imaging. We have used human
lung carcinoma (A549) and normal cardiomyocites (h9c2)
cell lines throughout all in vitro studies. We have assessed
MTT assay to determine the cytotoxity of our functional
PNPs. Results showed Taxol® and AzT encapsulated PNPs
were toxic to the cancerous cell lines, whereas, dye encapsulated polymeric fluorophores were non-toxic. These results
were corroborated with confocal microscopic studies and
FACS analysis. The PNPs degradation and controlled drug
and dye release experiments were performed under enzymatic and low pH environments. Most importantly, we are
successful in animal imaging using mice model, in vivo, with
the NIR dye (DiR and DiD) encapsulated PNPs for animal
imaging applications.
Therefore, our present protocol is capable of creating a
library of multifunctional therenostic (therapeutics and opti-

cal diagnostics) polymeric nanoparticles for biomedical
applications including (a) encapsulated chemotherapeutic
agents (Taxol® and AzT) for HIV and cancer therapy, (b)
surface functionality (folic acid ligand) for cancer targeting,
(c) "click" -chemistry-based conjugation of targeting ligands,
(d) encapsulated NIR dyes for fluorescent imaging capabilities and (e) thermomechanical applications including luminescent, conductive, magnetic or radioprotection of the corresponding polymeric-metallic nanocomposites.
10
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Synthesis and Characterization of Biodegradable Hyperbranched Polymers
The amphiphilic hyperbranched polyester (HBPE 5) was
rationally designed for the development oftheranostic PNPs
(nanoparticles providing both a therapeutic agent and a diagnostic modality), by employing strategies of nanoparticle
formation and drug/dye encapsulation in one process. FIG.
1-2 shows our synthetic strategy, leading to the formation of
a novel, water soluble, AB 2 monomer 4 which upon polymerization gives rise to the water insoluble, biodegradable polymer 5, capable of encapsulating dyes/drugs for therapeutic
applications. The melt polymerization technique was followed for the polymer synthesis, where we observed that at
the initial stages of polymerization, oligomers and low
molecular weight polymers were obtained. However, upon
applying vacuum, a high molecular weight polymer (Mw=42,
000, PD=l.6) was formed (FIG. 9). The resulting polyester
was highly branched, having carboxylic acid groups at the
surface and obtaining a three dimensional architecture with
hydrophobic cavity. Hence contrary to conventional linear
polyesters, our branched polymer is amorphous, amphiphilic,
soluble, highly surface functional, biodegradable and has a
cavity for effective encapsulation of guest molecules, which
suggest its versatility in biomedical applications. Through
thermal gravimetric analysis (TGA), we determined that the
polymer exhibits moderate thermal stability (10% weight loss
at 250° C. in air), which is typical for a biodegradable polymer (FIG. 10). The polymer was further characterized using
spectroscopic and chromatographic techniques (FIG. 5-8).
Subsequently, the presence of free carboxylic acid groups at
the surface prompted the generation of a library of functional
polymers using carbodiimide chemistry. We used 1,1'-carbonyldiimidazole (CDI), as a water insoluble carbodiimide, and
eitherethylenediamine orpropargylamine forthe synthesis of
surface-aminated cationic polymer (HBPE-EDA 6) and
clickable polymer, respectively (HBPE-PA 9, FIG. 3). Hence,
the former surface-aminated polymer may be a good candidate for non-specific cell internalization, whereas, the later
one might be a platform for targeted therapy due to the facile
conjugation of specific cellular receptor ligands, such as folic
acid, via click chemistry (FIG. 4).
Polymeric Nanoparticle (PNP) Synthesis and Drug/Dye
Encapsulation
In order to prepare functional PNPs, a modified solvent
diffusion method was used, where the nanoparticle formation
and guest molecule encapsulation in the hydrophobic cavity
took place in one-pot. The amphiphilic polymer and hydrophobic guests were dissolved in anhydrous dimethylformamide (DMF) and added drop-wise to water under continuous
stirring, driving both the self-assembly and encapsulation
processes and resulting in the synthesis of functional PNPs.
The resulting PNPs were highly stable in aqueous buffered
solution for more than a year, without significant reduction in
the fluorescent emission of the encapsulated dyes and can be
concentrated without significant precipitation. Therefore,
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near infra red dye (DiI, DiR and DiD) encapsulated PNPs
(Sa-c and 9a-c) were synthesized from the corresponding
carboxylated and aminated polymers (HBPE 5 and HBPEEDA 6, respectively). Alternatively, the aminated PNPs (9ac) can be prepared from the carboxylated PNPs (Sa-c) using
water soluble carbodiimide, EDC, [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride] and ethylenediamine (FIG. 3). Amination of these nanoparticles was confirmed by an overall surface charge Cs-potential)
measurement, where a positive surface potential was
obtained in the case of aminated PNPs (FIG. 20). Propargylated PNPs were also synthesized with DiI dye (1 Oa), DiR dye
(!Ob), DiD (lOc), DiI with the anti-cancer drug paclitaxel
(lOd) and with AzT (lOe) using the above strategy. These
PNPs (1 Oa-e) are very important synthon for the synthesis of
a library of functional PNPs via click chemistry. To demonstrate the applicability of click chemistry in this system, the
alkyne-azide click was engineered to occur at the interface
between the propargylated carboxylic acid corona of the
PNPs and the aqueous phase in which the azide-functionalized folic acid is dissolved. Therefore, folate-decorated PNPs
(lla-e) were prepared using this 1,3-dipolar cycloaddition
reaction, click chemistry, mediating the targeted drug delivery to cancer cells that overexpress the folate receptor (FIG.
4).
Polymeric Nanoparticle Characterization
The approximate hydrodynamic diameter of the PNPs was
determined though Dynamic Light Scattering (DLS), ranging
from 100±20 nm, which was similar to that of the unmodified
nanoparticles (FIG. 12). Well-formed spherical PNPs were
observed by scanning electron microscopy (SEM, FIG. 13)
and the average diameter of these PNPs was 115±25 nm,
demonstrating a direct correlation with the DLS data.
Remarkably, the black rectangular box in the SEM image
indicates that the shape of the nanoparticles was spherical as
expected from the structure of the original polymer HBPE 5.
The formation of hydrophobic microdomains and the encapsulation of NIR dyes inside the PNPs were confirmed by
fluorescence measurement of free DiI dye and encapsulated
DiI in PNPs (Sa, FIG. 18). In this experiment, DiI dye was
dissolved in DMF and allowed to evaporate at room temperature and then dispersed in water. A blue shift (by 23 nm) was
observed in the fluorescence emission of Dil-encapsulated
HBPE nanoparticles (570 nm) as compared to the free nonencapsulated DiI dye (593 nm) in water. This indicated the
presence of the dye inside the electronic environment of the
polymer's cavity, confirming the presence of hydrophobic
microdomains in the PNPs. Similar results were obtained
from UV/Visible spectroscopy studies, where a blue shift was
observed for the encapsulated DiI (FIG. 17), further confirming the entrapment of the dye inside the cavity. Interesting
results were obtained from Fourier Transform Infra Red (FTIR) spectroscopy (FIG. 14), and these corroborated the formation of PNPs encapsulating the DiI dye. The presence of
the aliphatic alkenes' characteristic band at 1675 cm- 1 indicated the encapsulation of DiI via conjugated double bonds
inside the nanoparticle cavity. Subsequently, we prepared
three different dye (DiI, DiR and DiD) containing PNPs (Sa,
Sb and Sc, respectively) from the polymer 5 as shown in FIG.
3 and FIG. 15. Characteristic fluorescence emission spectra
of the dye-loaded PNPs in PBS buffer are shown in FIG. 16.
The fluorescence intensity maxima of these nanoparticles
were at 570, 675 and 7SO nm, indicating the presence of the
NIR dyes DiI, DiD and DiR, respectively, within the hydrophobic domain of the PNPs. These functional fluorophorecontaining PNPs were highly stable in aqueous solution (FIG.

11). Next, NIR dye and paclitaxel co-encapsulated folate-
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clickedPNPs (1 la-e) were characterized by UV/Vis spectroscopy (FIG. 22-23).
In Vitro Cytotoxicity
Having in mind the potential biomedical applications of
the synthesized PNPs, we evaluated their cytotoxicity,
through the MTT assay. First, we examined the potential in
vitro differential cytotoxicity of carboxylated, aminated, and
folate-decorated Dil-containing PNPs, using a lung carcinoma (A549) cell line. Results indicated that the carboxylated
and folate-conjugated PNPs exhibited nominal cellular cytotoxicity (less than 4% compared to the control), whereas the
aminated PNPs induced cell death to approximately 10% of
the cell population (FIG. 24a). Considering these findings,
the potential use of these PNPs in imaging and drug delivery
applications, either in vitro or in vivo, is anticipated. Hence,
we examined if PNPs can be used for targeted drug delivery,
by examining the cytotoxic efficacy of PNPs co-encapsulating DiI and the hydrophobic chemotherapeutic agent paclitaxel. Indeed, the folate-decorated DiI and paclitaxel co-encapsulating PNPs induced a significant reduction in cell
viability, as more than 50% of the cell population underwent
cell death (FIG. 24b ). Furthermore, as most lung carcinomas
exhibit aberrant telomerase activity, leading to cell immortality, we encapsulated the reverse transcriptase inhibitor AzT in
PNPs. We found that folate-decorated DiI andAzT co-encapsulating PNPs induced significant cell death, as previously
reported in literature via inhibition of telomerase activity
(FIG. 24b). Overall, these data suggest that the induction of
cell death is mainly mediated by either paclitaxel or AzT, and
not by the fluorophore. Specifically, the enhanced in vitro
cytotoxicity of the folate-decorated DiI and paclitaxel coencapsulating PNPs inA549 cells hints the successful targeting of carcinomas that overexpress the folate receptor on their
plasma membrane. Furthermore, these results suggest that the
co-encapsulation of a fluorophore and a therapeutic agent in
our PNPs can be utilized for cellular targeting, such as in
cancer or anti-HIV CD4+-specific therapeutic regimes, visualization of the drug's homing and monitoring of tumor
regression in clinical studies.
In Vitro Cellular Uptake of PNPs
To demonstrate the capability of our functional PNPs to be
internalized by cells and eventually exert specific intracellular activity, various preparations of PNPs were incubated with
lung carcinoma cells (A549) for 6 h. Confocal images showed
there was no internalization of the non-aminated PNPs, but
only the cell membranes were found to be stained with the red
DiI dye (outer red lines, FIG. 25). This demonstrates the
proof-of-concept that the anionic (carboxylic groups at surface) PNPs are not appropriate candidates for cell internalization. To further corroborate this concept, we used A549
cells treated with aminated PNPs encapsulating DiI (9a).
Contrary to the carboxylated PNPs, there was strong internalization of the cationic surface PNPs (FIG. 26). Notably,
these PNPs did not affect cellular integrity and nuclear stability, failing to trigger apoptosis, even after 12 h of incubation. Hence, these results strongly support the notion that
cationic (surface amine groups) PNPs are better vehicles for
cell internalization. Subsequently, we performed in vitro cellular uptake studies, utilizing a Xenogen IVIS system. Similar results to the confocal studies were obtained. Specifically,
aminated PNPs were found intracellularly, as fluorescent
emission was recorded from the cell pellet. On the other hand,
there was absence of fluorescence emission from the pellet of
cells treated with non-aminated PNPs, suggesting lack of
PNP internalization (FIG. 21, IVIS images). Similar results
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were obtained from other synthesized PNPs (Sb-c and 9b-c)
through the IVIS setup, in line with the confocal microscopy
observations.
Then, we investigated the targeting potential of our PNPs
and cellularuptake of the folate-clicked PNPs (11 a), comparing these PNPs with the corresponding carboxylated ones
(Sa). Confocal microscopy revealed the effective uptake of
the folate-functionalized PNPs by A549 cells (FIG. 27), in
contrast to the carboxylated ones (FIG. 25). The enhanced
cellular uptake of the folate-decorated PNPs may be attributed to folate-receptor mediated internalization. Accordingly,
through confocal studies, we observed that the efficiency of
folate-decorated PNPs uptake significantly improved upon
increasing the incubation time, while no cytotoxic effects
were observed via the MTT assay. Hence, the enhanced timedependent uptake and retention of these PNPs is likely due to
folate-receptor recycling, which is typical of constitutive
nutrient receptor endocytic trafficking. Subsequently, to demonstrate the folate-clicked PNPs' (1 la) proof-of-concept
theranostic capability towards cancer cells, we used DiI and
paclitaxel co-encapsulating PNPs (lOd). Then, the surface
propargyl groups were clicked with azide-functionalized
folic acid, in order to achieve targeted drug delivery with
optical imaging capability for spatiotemporal monitoring.
Lung carcinoma cells overexpressing the folate receptor were
treated with these PNPs (1 ld). After a 3 h-long incubation,
confocal microscopic examination revealed cellular internalization and induction of paclitaxel-mediated mitotic arrest
(FIG. 28), in accordance to the literature. This illustrates that
paclitaxel' s therapeutic efficacy was preserved, despite its
PNP encapsulation. Furthermore, treatment with paclitaxelcontaining PNPs triggered dramatic cellular morphological
changes after 12 h of incubation, leading to cell death. Furthermore, as most lung carcinomas exhibit aberrant telomerase activity, leading to cell immortality, we encapsulated
the reverse transcriptase inhibitor AzT in PNPs. We found that
folate-decorated DiI and AzT co-encapsulating PNPs
induced significant cell death, as previously reported in literature via inhibition oftelomerase activity (FIG. 29). These
observations strongly support the importance of encapsulating this potent anti-tumor agent within the polymeric cavity
and targeting its delivery, in order to prevent damaging nontransformed cells and healthy tissue. Taken together, these
findings support the principle that folate-decorated PNPs can
target and deliver chemotherapeutic agents to folate-receptoroverexpressing carcinomas, while visualizing the drug's
homing. Thus by modifying the targeting moiety at the theranostic PNPs' surface, other carcinomas or ailing cells may be
targeted tailoring the therapeutic regime, while obtaining
important spatiotemporal information for clinical decision
making.
Flow Cytometric Assessment of PNPs Uptake
To corroborate the PNPs cellular uptake ability, a detailed
flow cytometry analysis was performed with functional PNPs
(Sa, 9a and 1 la) and A549 cells. Specifically, through flow
cytometry, we determined the Dil-derived cell-associated
fluorescence emission in a quantifiable fashion. As shown in
FIG. 30b, limited fluorescence emission was observed from
cells treated with the carboxylated PNPs (Sa). This indicated
nominal cell association of these carboxylated PNPs (Sa),
when compared to the control non-treated cells (FIG. 30a)
where there was lack of fluorescence emission. This is in
accordance with the data from the confocal and IVIS studies,
confirming the observation that the anionic surface of the
nanoparticles interacts with the cell's plasma membrane.
Contrary to this and similar to the confocal microscopic
observations, cells incubated with aminated PNPs (9a)

showed three-fold higher fluorescence emission and binding
activity when compared to the control mock-treated cells, as
shown in FIG. 30c. Similar to other cationic small molecules
and peptides, the interaction of the surface-localized positive
charge of the aminated PNPs with the negatively charged cell
membrane facilitated the association of the PNPs with the cell
membrane at the extracellular milieu and the subsequent cellular uptake and retention, as observed through previously
discussed in vitro studies. Interestingly, upon clicking the
carboxylated PNPs with folic acid, a higher cell-associated
fluorescence emission was observed (FIG. 30d). Notably, the
profound cellular uptake of the folate-decorated PNPs (1 la),
being comparable to the aminated ones, is attributed to the
specific folate-receptor-mediated internalization and intracellular retaining. Overall this indicates that the specific targeting of PNPs through targeting moieties, such as folate, is
feasible and equally efficient as the non-specific electrostaticmediated uptake of cationic entities, rendering targeted PNPs
useful for potential in vivo applications.
Drug/Dye Release Study of Functional PNPs
The therapeutic application of our polymeric nanoparticles
is influenced by the rate of release of the encapsulated drug
from the polymeric cavity. To evaluate 1 ld's drug release
profile, enzymatic (esterase) and low-pH degradation experiments were performed. Results indicate a fast release of the
drug (paclitaxel) from the nanoparticle 1 ld upon esterase
incubation, reaching a plateau within 4 hours (FIG. 31A). A
similar release profile of the drug was observed at pH 4.0,
reaching a plateau within 4 .5 hours (FIG. 3 lB). No significant
release of the drug was observed from nanoparticles incubated in PBS, pH 7.4. These results demonstrate the stability
of the polymeric nanoparticles during storage (PBS), and
their cargo release only after cellular uptake via either
esterase-mediated degradation or in acidified lysosomes.
Only after folate-receptor-mediated uptake did the PNPs 1 ld
become cytotoxic upon intracellular release of the therapeutic
agent. Interestingly, even slower release of the dye was
observed, both upon esterase incubation and at pH 4.0 (FIGS.
31C and 31D). However, no release of the dye was observed
at normal physiological pH (7.4). The observed differential
release of the drug vs. the dye from PNPs 1 ld may be attributed to the drug's (paclitaxel) size and hydrophobic nature.
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Materials
Anhydrous DMF, DMSO, 3-(4,5-Dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT), 1,1'-Carbonyldiimidazole (CDI), N-hydroxysuccinimide (NHS), AZT (azidothymidine), diethylmalonate and other chemicals were
purchased from Sigma-Aldrich and used without further purification. Near Infra Red dyes (DiI-D2S2, DiD-D7757, and
DiR-D12731) and 4', 6-diamidino-2-phenylindole (DAPID1306) were purchased from Invitrogen, whereas the EDC
(1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) was obtained from Pierce Biotechnology. The
folate-receptor-overexpressing human lung carcinoma cell
line A549 (CCL-1S5) was obtained from ATCC. Dialysis
membranes were obtained from Spectrum Laboratories.
Acetonitrile, tetrahydrofuran and other solvents were purchased from Fisher Scientific and used as received, unless
otherwise stated.
Instrumentation
Infrared spectra were recorded on a PerkinElmer Spectrum
100 FT-IR spectrometer. UVNis spectra were recorded using
CARY 300 BiO UV/Vis spectrophotometer. Fluorescence
spectra were recorded on a NanoLog Horiba jobin Yvon
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fluorescence spectrophotometer. NMR spectra were recorded
on a MERCURY 300 MHz spectrometer using the TMS/
solvent signal as an internal reference. Gel permeation chromatography (GPC) results were obtained using JASCO MD
2010 Plus instrument with PD 2020 light scattering Precision
Detector. Thermo gravimetric analyses (TGA) were performed on a SETARAM, Mettler TCl 1 instrument with
sample sizes 10-20 mg. All the experiments were done using
a heating rate of 10° C./min in air. Atomic Force Microscopic
(AFM) images were obtained from Dimension 3100 Atomic
Force Microscope from Veeco Digital Instruments. Confocal
images were taken on a Zeiss Axioskop 2 mot plus confocal
microscope. Flow Cytometry experiments were performed
using a BD FACS Calibur multipurpose flow cytometer system from BD Biosciences. MTT study has been done using
BIO-TEK Synergy HT multi-detection microplate reader.
Dynamic light scattering (DLS) studies were done using a
PDDLS/Coo!Batch 40T instrument using Precision Deconvolve 32 software and SEM images were taken using Jeol
6400F scanning electron microscope. IVIS experiments were
done using IVIS 50 imaging system from Xenogen imaging
technologies. Analytical Thin Layer Chromatography (TLC)
was performed on glass plates coated with silica gel GF 254
and are visualized in iodine vapor. Colunm chromatography
wasperformedusingsilicagel(100-200mesh)andtheeluant
is mentioned in the procedures below for each case.

51.84, 61.27, 63.89, 169.31, 171.11.IR (CHC1 3): 2982, 1728,
1463, 1367, 1233, 1151, 1029, and 860 cm- 1.
Synthesis of 2-( 4-hydroxy butyl)-malonic acid (4)
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Methods
Synthesis of 4-bromobutyl acetate (2)
Tetrahydrofuran (12.2 mL, 148.4 mmol) and potassium
bromide (21.1 g, 176.5 mmol) were added in a 250 mL round
bottom flask containing 150 mL acetonitrile. The reaction
mixture was cooled to 0° C., followed by drop-wise addition
of acetyl chloride (11 mL, 155.1 mmol). Subsequently, the
mixture was brought to room temperature, where it was continuously stirred for 3 6 h. The reaction mixture was poured in
water and extracted with ethyl acetate. The organic layer was
washed with water, dried over Na 2S04 , and concentrated to
obtain the pure product as a colorless liquid.
Yield: 24.3 g (85%). bp: >250° C. 1H NMR (300 MHz,
CDC1 3, ll ppm, J Hz): 1.79 (m, 2H), 1.92 (m, 2H), 2.03 (s, 3H),
3.46 (t, 2H, J=7.6), 4.08 (t, 2H, J=6.7). 13 C NMR (75 MHz,
CDC1 3, ll ppm): 20.87, 27.36, 29.36, 33.03, 63.43, 170.95. IR
(CHC1 3): 3038, 2926, 1352, 1243, 1052 cm 1.
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Synthesis of 2-( 4-Acetoxy-butyl)-malonic acid
diethyl ester (3)
50

Compound 3 was prepared by following a previously
reported method.{Santra, 2004 #6} Briefly, diethyl malonate
1 (10 g, 62.5 mmol), 4-bromobutyl acetate 2 (15.84 g, 81.3
mmol) were placed in a round bottom flask containing acetonitrile (120 mL) and stirred for 2 min at room temperature.
Then to this, we added potassium carbonate (34.5 g, 250.1
mmol) and refluxed for 36 h. Next, the mixture was filtered
and the filtrate was concentrated to obtain a yellow liquid.
This was extracted with ethyl acetate, and washed with water.
The organic layers were combined and dried over Na 2S04 ,
and purified by colunm chromatography using 4% ethyl
acetate in petroleum ether as the eluent.
Yield: 13.02 g (76%). bp: 250° C. 1H NMR (300 MHz,
CDC1 3, ll ppm, J Hz): 1.28 (t, 6H, J=7.6), 1.38 (m, 2H), 1.62
(q, 2H, J=7.2), 1.98 (q, 2H, J=7.7), 2.05 (s, 3H), 3.34 (t, lH,
J=7.7), 4.09 (t, 2H, J=6.6), 4.22 (q, 4H, J=7.2). 13 C NMR (75
MHz, CDC1 3, ll ppm): 14.06, 20.79, 23.74, 28.25, 28.25,

2-(4-acetoxy-butyl)-malonic acid diethyl ester 3 (5.0 g,
18.25 mmol, see Section S 1 in the Supporting Information for
the synthesis of compound 3) was taken in a 100 mL round
bottom flask containing methanol (50 mL) and stirred at room
temperature for 2 min. To this was added NaOH (2.1 g, 54.74
mmol) in water (7 mL) and stirred at 90° C. for 8 h. The
reaction mixture was shifted to room temperature and acidified (pH 2-3) with the drop-wise addition of dilute hydrochloric acid at room temperature with constant stirring. The mixture was then concentrated by using rotary evaporator and
applying vacuum. To this was added chloroform (50 mL) and
Argon gas was bubbled through the solution at 60° C. to
remove excess HCI. The mixture was filtered and the filtrate
was concentrated. This was then purified by colunm chromatography using 35% ethyl acetate in petroleum ether as eluent.
1
Yield: 2.31 g (72% ). H NMR (300 MHz, CDCl3, ll ppm, J
Hz): 1.41 (m, 2H), 1.59 (m, 2H), 1.91 (q, 2H, 11=7.3,12=7.8),
13
3.37 (t, lH, J=7.4), 3.64 (t, 2H, J=6.5), 5.54 (bs, lH). C
NMR (75 MHz, CDC1 3, ll ppm): 23.53, 28.52, 31.75, 52.64,
62.11, 170.55. IR (CHC1 3): 3507, 2941, 1710, 1626, 1459,
1438, 1391, 1198, 1157, 1050, 947, 772, 741, 664 cm- 1.
Synthesis of Hyperbranched Polyester (HBPE) 5
The monomer 4 and the catalyst p-toluene sulphonic acid
(100: 1 molar ratio) were taken in a 10 mL round bottom flask
and dried under high vacuum followed by the release of
vacuum using dry argon gas. Then the flask was slowly heated
to 150° C. under argon atmosphere using an oil bath and it was
kept at this temperature for 2 h. The evolution of the byproduct (water vapor) was clearly visible after the sample was
heated at 150° C. The melt was evacuated at 0.2 mm/Hg for 1
h while maintaining the same polymerization temperature.
The polymer was purified by dissolving in DMF and reprecipitating in methanol. This was then centrifuged, washed
with methanol and dried in a high vacuum pump to get pure
polymer.
Yield: 65%. 1H NMR (300 MHz, DMSO-d6 , ll ppm): 1.25
(m, 2H), 1.52 (m, 2H), 1.67 (m, 2H), 3.38 (m, lH), 3.58 (m,
2H), 5.28 (m, lH). 13 C NMR (75 MHz, DMSO-d6 , ll ppm):
23.82, 28.23, 51.85, 52.63, 65.37, 170.45. IR: 2954, 1727,
1458, 1436, 1343, 1218, 1152, 1054, 943, 858, 743, 694
cm- 1. TGA: 10% weight loss at 250° C.
Synthesis of Hyperbranched Polyester Amine
(HBPE-EDA) 6: Carbodiimide Chemisrty
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The polymer 5 (0.1 g, 0.0025 mmol) was dissolved in
anhydrous DMF (1 mL) using vortex mixture and to this was
added 1,1'-carbonyldiimidazole CDI (0.041g,0.25 mmol) in
anhydrous DMF (0.1 mL) drop-wise. The reaction mixture
was incubated for 2 h at room temperature. To this was then
added ethylenediamine (0.015 g, 0.25 mmol) in anhydrous
DMF (0.4 mL) drop-wise and incubated at room temperature
for 24 h. The resulting reaction mixture was then precipitated
in methanol, centrifuged and dried in a vacuum pump to get
pure aminated polymer.
Yield: 88%. 1H NMR (300 MHz, DMSO-d6 , ll ppm): 1.27
(m, 2H), 1.55 (m, 2H), 1.74 (m, 2H), 2.26 (m, 4H), 2.88 (m,
4H), 3.34 (m, lH), 3.63 (m, 4H), 4.04 (m, 2H). IR: 3245,
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2940,2864,1725,1659,1534,1435,1240,1159,1062,1021,
952, 929, 826, 749, 704, 663 cm- 1 .

flash colunm chromatography using 4% ethyl acetate in
petrolium ether as an eluant, in order to obtain the pure
aminopropylazide.
Yield: 5.1 g (68%). 1 H NMR (300 MHz, CDC1 3 , ll ppm):
1.26 (bs, 2H), 1.81 (m, 2H), 2.80 (t, 2H), 3.38 (t, 2H). IR
(CHC1 3 ): 3307, 2941, 2089, 1663, 1433, 1370, 1259, 1242,
1075, 1026, 818, 760 cm- 1 .

Synthesis of Clickable Hyperbranched Polyester
(HBPE-PA) 7: Carbodiimide Chemistry
Similar procedure has been followed as described for the
synthesis of polymer 6. Instead of ethylenediamine, propargylamine (0.014 g, 0.25 mmol) was used as the starting material.
Yield: 80%. 1 HNMR (500 MHz, DMSO-d 6 , llppm): 1.28
(m, 2H), 1.54 (m, 2H), 1.75 (m, 2H), 2.25 (m, 2H), 3.42 (bs,
lH), 3.96 (m, 4H), 4.03 (m, 2H). IR: 3121, 2938, 2864, 2698,
2607, 1725, 1664,1530, 1458,1437, 1388, 1326,1254, 1158,
1094, 1062, 929, 827, 748, 662 cm- 1 .
General Procedures for the Synthesis of Functional
Polymeric Nanoparticles Dye-Encapsulating PNPs
(8-10): Solvent Diffusion Method
Different near IR dye (DiI, DiR or DiD) solutions were
prepared by mixing 5 µL of the dye aliquot (10 µg/µL) in 250
µL ofDMF. The polymers (5, 6 or 7, 0.025 g) were dissolved
in 250 µL of anydrous DMF using a vortex mixturer and
mixed seperately with different dye solution. The resulting
polymer-dye mixture in DMF was added drop-wise to deionized water (5 mL) with continuous stirring at room temperature forming dye encapsulated polymeric nanoparticle. The
nanoparticle solution was dialyzed (using 6-8 K molecular
weight cut off dialysis bag) three times against deionized
water and phosphate buffered saline (PBS) solution.
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Synthesis of Azide-Functionalized Folic Acid 13
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Paclitaxel (Taxol@) and DiI co-encapsulating
polymeric nanoparticles 1Od

35

Taxol® (5 µL, 1 mg/mL) andDiI dye (5 µL, 10 µg/µL)were
taken in an EppendorfTube® containing propargylated polymer (7, 0.025 g) in 500 µL DMF and followed the solvent
diffusion method as described above.

40

AZT and DiI Co-Encapsulating Polymeric
Nanoparticles lOe
AZT (azidothymidine) was dissolved in DMF to a final
concentration of 1 mg/mL. The polymers (5 or 7, 0.025 g)
were dissolved in 250 µL of DMF using a vortexer. Subsequently, AZT (5 µL, 1 mg/mL) andDiI (5 µL, 10 µg/mL)were
added to the polymer solutions, followed by vortexing. The
resulting polymer-AZT-Di! mixture in DMF was added dropwise to deionized water (5 mL) with continuous stirring at
room temperature forming DiI and AZT co-encapsulating
polymeric nanoparticles. The nanoparticle solutions were
dialyzed (using 6-8 K molecular weight cut off dialysis bag)
three times against deionized water and phosphate buffered
saline (PBS) solution.
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Synthesis ofAminopropylazide 12
Chloropropyl amine (7 .0 g, 7 5 .26 mmol) and sodium azide
(14.23 g, 225.81 mmol)weretakenina lOOmLround bottom
flask containing 40 mL of distilled water and heated at 80° C.
for 20 h. The reaction mixture was concentrated via a
rotavapor using high vacuum, and 2 g of KOH was added to it
and then extracted by using diethyl ether. Subsequently, the
reaction mixture was dried over anhydrous sodium sulphate
and concentrated. Then, the mixture was purified through
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1,1'-carbonyldiimidazole CDI (0.022 g, 0.014 mmol) was
taken in an Eppendorf Tube® containing folic acid (0.05 g,
0.011 mmol) in anhydrous DMF (2 mL) and incubated for 2
hat35° C. To this weaddedaminopropylazide (0.014 g, 0.014
mmol) in anhydrous DMF (100 µL) and incubated it for 24 h
at room temperature. The reaction mixture was then cetrifuged and washed to remove excess starting materials.
Finally, we dissolved the azide-functionalized folic acid in 1
mL of DMF. The presence of a band at 2091 cm- 1 in the IR
spectrum and a UV absorbance shoulder at 354 nm confirmed
the formation of azide-functionalized folic acid.
Yield: 0.05 g (86%). 1 H NMR (400 MHz, DMSO-d6 , ll
ppm): 1.61(m,2H), 1.65 (m, 2H), 1.90 (m, 2H), 2.19 (t, 2H),
2.78 (t, 2H), 4.18 (q, lH), 4.21(d,2H), 6.62 (d, 2H), 7.59 (d,
2H), 8.58 (s, lH). FT-IR (Neat): 3024, 2097, 1685, 1603,
1492,1375,1291,1248,1180,1122,1062,950,844,755,696
cm- 1 .
Synthesis of Folate-Functionalized PNPs 1 la-e:
Click Chemisrty
The propargylated polymeric nanoparticles 1Oa-e (0.025 g,
6x10- 3 mmol) in bicarbonate buffer (pH=8.5) were taken to
an eppendorf containing catalytic amount of Cul (0.11 µg,
6xl 0- 10 mmol) in 250 µL of bicarbonate buffer, vortexed for
30 seconds. To this was added azide-functionalized folic acid
(13, 0.003 g, 6x10- 2 mmol) in DMSO and the reaction was
incubated at room temperature for 12 h. The final reaction
mixture was purified by dialysis using 6-8 K molecular
weight cut off dialysis bag, against deionized water and phosphate buffered saline (PBS) solution. The purified functional
PNPs (lla-e) were stored in refrigerator for further characterization.
Cell Culture and Cell Viability Studies
Lung carcinoma cells (A549) were grown in Kaighn's
modification of Ham's F12 medium (F12K-Cellgro ), supplemented with 5% fetal bovine serum (Heat-inactivated FBSCellgro ), L-glutamine, streptomycin, amphotericin B, and
sodium bicarbonate. The cells were maintained at 37° C., 5%
C0 2 in a humidified incubator. We used the MTT assay in
order to assess potential cytotoxic effects upon in vitro
administration of the drug/dye-encapsulating functional
HBPE nanoparticles. Specifically, lung carcinoma cells
(3000 cells/well) were seeded in 96-well plates, and were
incubated with the nanoparticles for 3 hours at 37° C. Then,
each well was washed three times with lxPBS and treated
with 20 µl MTT (5 µg/µl, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazo-lium bromide, Sigma-Aldrich) for 2 hours.
The resulting formazan crystals were dissolved in acidified
isopropanol (0.1 N HCl) and the absorbance was recoded at
570 nm and 750 nm (background), using a Synergy HT multidetection microplate reader (Biotek). These experiments
were performed in triplicates.
Cellular Internalization
Initially, in vitro uptake and internalization of the PNPs
was assessed through fluorescence laser-scanning confocal
microscopy, using a Zeiss LSM 510 confocal microscope.
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Specifically A549 cells (10 3 ) were incubated for the stated
time period with the corresponding PNP preparation in a
humidified incubator (37° C., 5% C0 2 ). Subsequently, the
cells were thoroughly washed three times with 1xPBS and
fixed with a 10% formalin. Nuclear staining with DAPI was
performed as recommended by the supplier. Then, multiple
confocal images were obtained, achieving a representative
view of the cell-PNP interaction. Confirmation of the confocal studies was facilitated through FACS and IVIS analyses.
For FACS, 105 lung carcinoma cells were incubated for 6
hours with the corresponding PNP preparation. Then the cells
were detached from the culture dish with 0.05% trypsin, and
the resulting pellet was resuspended in 1 mL culture media.
The cell suspension underwent flow cytometric analysis,
using a BD FACSCalibur system, in order to quantify the
cellular uptake of the synthesized PNPs. For the IVIS analysis, 105 lung carcinoma cells were incubated for 6 hours with
the corresponding PNP preparation, and then the supernatant
was collected in eppendorf tubes. Subsequently, we thoroughly washed the cells with lxPBS and detached them, as
stated above. The resulting pellets were resuspended in 1 ml
culture media. All EppendorfTubes® were examined simultaneously on a Xenogen IVIS sytem, using the following filer
sets: DsRed (500-550 nm/575-650 nm for Dil), Cy5.5 (615665 nm/695-770 nm for DiD) and ICG (710-760 mn/810-875
nm for DiR). All experiments were performed in triplicates.
In vitro drugldye release:
The in vitro drug/dye release studies were carried out using
a dynamic dialysis technique at 37° C. Briefly, 100 µL of
PNPs (11 d) are incubated with a porcine liver esterase (20 µL)
inside a dialysis bag (MWCO 6000-8000), which is then
placed in a PBS solution (pH 7.4). The amount of guest (dye
or drug) molecules released from the nanoparticle into the
PBS solution was determined at regular time intervals by
taking 1 mL aliquots from the PBS solution and measuring
the fluorescence intensity at 575 nm for Dil and 372 nm for
Taxol®®. The concentration of the either dye or drug was
calculated using a standard calibration curve. The cumulative
fraction of release versus time was calculated using the following equation:

[5] Kataoka, K.; Kwon, G. S.; Yokoyama, M.; Okano, T.;
Sakurai, Y. J. Controlled Release 1993, 24, 119-132.
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Cumulative release(% )~[guest]/[guest l<a<alx 100

Where [guest], is the amount of guest released at time t,
[guest ltotaZ is the total guest present in the guest encapsulated
PNPs.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.

What is claimed is:
1. A polymer comprising the repeating unit
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2. A polymeric nanoparticle comprising the polymer of
claim 1.
3. The polymeric nanoparticle of claim 2, further comprising a hydrophobic near-infrared fluorescent dye encapsulated
therein.
4. The polymeric nanoparticle of claim 3, wherein the dye
is selected from the group consisting of Dil, DiR, DiD, and
combinations thereof.
5. The polymeric nanoparticle of claim 2, further comprising a therapeutic drug encapsulated therein.
6. The polymeric nanoparticle of claim 5, further comprising a fluorescent dye co-encapsulated with said therapeutic
drug.
7. The polymeric nanoparticle of claim 5, wherein the
therapeutic drug comprises an anti-cancer drug.
8. The polymeric nanoparticle of claim 5, wherein the
therapeutic drug comprises azidothymidine.
9. The polymeric nanoparticle of claim 2, wherein the
polymeric nanoparticle is biodegradable.
10. The polymeric nanoparticle of claim 2, having one or
more internal hydrophobic pockets and a hydrophilic outer
surface.
11. The polymeric nanoparticle of claim 2, having an average diameter of 115±25 nm.
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12. The polymeric nanoparticle of claim 2, being spherical
in shape.
13. The polymeric nanoparticle of claim 2, having a negative zeta potential.
14. An aqueous suspension of the polymeric nanoparticle
of claim 2.
15. The aqueous suspension of claim 14, further comprising a hydrophobic near-infrared fluorescent dye.
16. The aqueous suspension of claim 14, further comprising a therapeutic drug.
17. The aqueous suspension of claim 14, further comprising a hydrophobic near-infrared fluorescent dye and a therapeutic drug.

* * * * *
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